Quanterix has entered a strategic agreement with bioMerieux providing the latter with worldwide exclusive rights to its Simoa technology for use in clinical laboratories and industrial applications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pursuant to the agreement, Quanterix will develop a new instrument and consumables based on its Simoa technology and will receive upfront and milestone payments and royalties on future sales.

bioMerieux will develop ultra-sensitive and multiplex assays on the platform and will take an additional equity stake, based on achievement of certain milestones.

Biodesix and Bioyong Technology have signed a collaboration agreement for the joint development and commercialisation of Veristrat test, a precision medicine test for patients with non-small cell lung cancer (NSCLC).

Pursuant to the agreement, Biodesix will develop the former’s version of VeriStrat proteomic blood test and commercialise the same in China with potential expansion into other Asia-Pacific countries.

The companies will also develop new mass spectrometry-based assays in oncology and other clinical areas, as a part of the agreement.

Royal Philips and Illumina have joined hands to integrate the former’s IntelliSpace Genomics clinical informatics platform with the latter’s sequencing systems for large-scale analysis of genetic variation and function. The marketing and sales of the resulting solution will be jointly undertaken by both the companies.

The collaboration enables the two companies to integrate genomics solutions for oncology.

Second Sight Medical Products has announced rights offering of approximately 15 million units, each containing one common stock share and a warrant, to raise gross proceeds of $30m.

The company will also distribute one non-transferable subscription right for each common stock share.

“The companies will also develop new mass spectrometry-based assays in oncology and other clinical areas, as a part of the agreement.”

The amount raised from the offering will be used to fund ongoing product development, and for other operating and corporate general purposes.

10X Genomics and PerkinElmer have announced a collaboration to jointly offer automated next-generation sequencing (NGS) solutions.

Pursuant to the agreement, 10x’s Chromium system and PerkinElmer’s automation solutions will be combined into a NGS solution, which will meet the critical need of research communities for long-range, structural and cellular information

Image: A man working in a laboratory. Photo: courtesy of Royal Philips.